Compare PRI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRI | NUVL |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.3B |
| IPO Year | 2009 | 2021 |
| Metric | PRI | NUVL |
|---|---|---|
| Price | $281.05 | $101.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $294.00 | $134.75 |
| AVG Volume (30 Days) | 165.9K | ★ 469.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 67.10 | N/A |
| EPS | ★ 5.97 | N/A |
| Revenue | ★ $3,291,713,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $5.08 | $1,239.49 |
| P/E Ratio | $46.97 | ★ N/A |
| Revenue Growth | ★ 6.56 | N/A |
| 52 Week Low | $230.09 | $70.25 |
| 52 Week High | $288.03 | $113.02 |
| Indicator | PRI | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 47.79 |
| Support Level | $266.27 | $97.91 |
| Resistance Level | $287.39 | $107.72 |
| Average True Range (ATR) | 7.45 | 3.83 |
| MACD | 0.14 | -0.24 |
| Stochastic Oscillator | 68.83 | 29.93 |
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.